(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 December 2012 (06.12.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/166241 A1

(51) International Patent Classification:
G01N 33/574 (2006.01) *G01N 33/50* (2006.01)

(21) International Application Number:
PCT/US2012/031993

(22) International Filing Date:
3 April 2012 (03.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/492,603 2 June 2011 (02.06.2011) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BANDARU, Raj** [IN/US]; 12 Fairlane Terrace, Winchester, Massachusetts 01890 (US). **HAIDER, Asifa** [CH/US]; 53 Garden Court, Succasunna, New Jersey 07876 (US). **ROBINSON, Douglas, Michael** [US/US]; Novartis Institutes for BioMedical Research, Inc., 220 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **ROSE, Kristine, Lynn** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **SHARP, Thad, Tyson** [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **SHOU, Yaping** [CN/US]; 405 Arlington Street, Acton, Massachusetts 01720 (US).

(74) Agent: **MULKEEN, Matthew**; Novartis Pharmaceuticals Corporation, Patent Department, One Health Plaza, Bldg. 101, East Hanover, NJ 07936 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2012/166241 A1

(54) Title: BIOMARKERS FOR HEDGEHOG INHIBITOR THERAPY

(57) Abstract: A method of selecting a subject having cancer for treatment with a Hedgehog signaling inhibitor by determining the level of expression of at least one biomarker in a biological sample derived from the subject.